Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-11-06
1999-08-31
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
A61K 31135
Patent
active
059454563
ABSTRACT:
TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation of vascular smooth muscle cells over time. Further provided is a method for upregulating cellular mRNA coding for TGF-beta.
REFERENCES:
patent: 2914563 (1959-11-01), Allen et al.
patent: 3010965 (1961-11-01), Elpern
patent: 3168565 (1965-02-01), Palopoli et al.
patent: 3288806 (1966-11-01), DeWald et al.
patent: 3445473 (1969-05-01), Ruschig et al.
patent: 3634517 (1972-01-01), Palopoli et al.
patent: 4133814 (1979-01-01), Jones et al.
patent: 4219656 (1980-08-01), Press et al.
patent: 4230862 (1980-10-01), Suarez et al.
patent: 4235988 (1980-11-01), Fildes et al.
patent: 4282246 (1981-08-01), Holland
patent: 4307111 (1981-12-01), Crawley
patent: 4317915 (1982-03-01), Confalone et al.
patent: 4380635 (1983-04-01), Peters
patent: 4382143 (1983-05-01), Shepherd
patent: 4418068 (1983-11-01), Jones
patent: 4428963 (1984-01-01), Confalone et al.
patent: 4442119 (1984-04-01), Magarian et al.
patent: 4536516 (1985-08-01), Harper et al.
patent: 4696949 (1987-09-01), Toivola et al.
patent: 4767758 (1988-08-01), Breccia et al.
patent: 4824436 (1989-04-01), Wolinsky
patent: 4826672 (1989-05-01), Milius et al.
patent: 4839155 (1989-06-01), McCague
patent: 4859585 (1989-08-01), Sonnenschein et al.
patent: 4879315 (1989-11-01), Magarian et al.
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 4973755 (1990-11-01), Grafe et al.
patent: 4990538 (1991-02-01), Harris et al.
patent: 4996225 (1991-02-01), Toivola et al.
patent: 4997652 (1991-03-01), Wong
patent: 5015666 (1991-05-01), Magarian et al.
patent: 5032679 (1991-07-01), Brandley et al.
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5098903 (1992-03-01), Magarian et al.
patent: 5112305 (1992-05-01), Barath et al.
patent: 5120535 (1992-06-01), Marquardt et al.
patent: 5140012 (1992-08-01), McGovern et al.
patent: 5166143 (1992-11-01), Ondetti et al.
patent: 5171217 (1992-12-01), March et al.
patent: 5189046 (1993-02-01), Burch et al.
patent: 5189212 (1993-02-01), Ruenitz
patent: 5192525 (1993-03-01), Yang et al.
patent: 5208019 (1993-05-01), Hansson et al.
patent: 5216024 (1993-06-01), Markaverich et al.
patent: 5219548 (1993-06-01), Yang et al.
patent: 5221620 (1993-06-01), Purchio et al.
patent: 5238950 (1993-08-01), Clader et al.
patent: 5242397 (1993-09-01), Barath et al.
patent: 5254594 (1993-10-01), Niikura et al.
patent: 5268358 (1993-12-01), Fretto et al.
patent: 5270047 (1993-12-01), Kauffman et al.
patent: 5280016 (1994-01-01), Conrad et al.
patent: 5280109 (1994-01-01), Miyazono et al.
patent: 5283257 (1994-02-01), Gregory et al.
patent: 5284763 (1994-02-01), Derynk et al.
patent: 5288711 (1994-02-01), Mitchell et al.
patent: 5296492 (1994-03-01), Shiozawa et al.
patent: 5304541 (1994-04-01), Purchio et al.
patent: 5308622 (1994-05-01), Casscells et al.
patent: 5308862 (1994-05-01), Ohlstein et al.
patent: 5324736 (1994-06-01), Magarian et al.
patent: 5326757 (1994-07-01), Demopoulos
patent: 5362424 (1994-11-01), Lee et al.
patent: 5393763 (1995-02-01), Black et al.
patent: 5393785 (1995-02-01), Labrie et al.
patent: 5395842 (1995-03-01), Labrie et al.
patent: 5453436 (1995-09-01), Ohlstein
patent: 5453492 (1995-09-01), Butzow et al.
patent: 5468746 (1995-11-01), Casagrande et al.
patent: 5482949 (1996-01-01), Black et al.
patent: 5491173 (1996-02-01), Toivola et al.
patent: 5599844 (1997-02-01), Grainger et al.
patent: 5770609 (1998-06-01), Grainger et al.
Wolinsky, H., et al., "Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin into the Wall of the Normal Canine Artery", JACC, 15, 475-481 (Feb. 1990).
Zuckerman, S.H., et al., "Cytokine Regulation of Macrophage apo E Secretion: Opposing Effects of GM-CSF and and TGF-Beta", Atherosclerosis, 96, 203-214 (1992).
Steele, P.M., et al., "Balloon Angioplasty--Natural History of the Pathophysiological Response to Injury in a Pig Model", Cir. Res., 57, 105-112 (Jul. 1985).
Streuli, C.H., et al., "Extracellular Matrix Regulates Expression of the TGF-Beta.sub.1 Gene", J. Cell Biol., 120, 253-260 (Jan. 1993).
Suckling, K.E., "Emerging Strategies for the Treatment of Atherosclerosis as Seen from the Patent Literature", Biochem. Soc. Trans., 21, 660-662 (Mar. 30, 1993).
Vargas, R., et al., "Oestradiol Inhibits Smooth Muscle Cell Proliferation of Pig Coronary Artery", Br. J. Pharmacol., 109, 612-617 (1993).
Wakefield, L.M., et al., "Latent Transforming Growth Factor-Beta from Human Platelets: A High Molecular Weight Complex Containing Precursor Sequences.", J. Biol. Chem., 263, 7646-7654 (June. 5, 1988).
Wakefield, L.M., et al., "Recombinant Latent Transforming Growth Factor-Beta.sub.1, has a Longer Plasma Half-Life in Rats than Active Transforming Growth Factor-Beta.sub.1, and a Different Tissue Distribution.", J. Clin. Invest., 86, 1976-1984 (Dec. 1990).
Weissberg, P.L., et al., "Approaches to the Development of Selective Inhibitors of Vascular Smooth Muscle Cell Proliferation", Cardiovas. Res., 27, 1191-1198 (1993).
Weissberg, P.L., et al., "Effects of TGF-Beta on Vascular Smooth Muscle Cell Growth", In: Growth Factors and the Cardiovascular System, Cummins, P., (ed.), Kluwer Academic Publishers, Norwell, MA, pp. 189-205 (1993).
Weissberg, P.L., et al., "Is Vascular Smooth Muscle Cell Proliferation Beneficial?", Lancet, 347, 305-307 (Feb. 5, 1996).
Wilensky, R.L., et al., "Direct Intraarterial Wall Injection of Microparticles via a Catheter: A Potential Drug Delivery Strategy Following Angioplasty", Am. Heart J., 122, 1136-1140 (Oct. 1991).
Popma, J.J., et al., "Factors Influencing Restenosis after Coronary Angioplasty", Am. J. of Med., 88, 1-16N--1-24-N (Jan. 1990).
Rauterberg, J., et al., "Collagens in Atherosclerotic Vessel Wall Lesions", Current Topics in Pathology, 87, 163-192 (1993).
Reiner, Z., et al., "Antiestrogen Tamoxifen Reduces Lipoprotein(a)", Abstracts, The Second International Conference on Lipoprotein(a), New Orleans, LA, p. 124 (Nov. 12-14, 1992).
Ross, R., et al., "Chronic Inflammation, PDGF, TGF-Beta, and Smooth Muscle Proliferation", J. Cell Biol., S15C, p. 96, Abstract No. G006 (1991).
Ross, R., "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s", Nature, 362, 801-809, (Apr. 29, 1993).
Schoenemanne, B., et al., "The Differential Diagnoses of Spontaneous Pneumothorax and Pulmonary Lymphangioleimyomatosis Clinical Picture Diagnoses and Theory", Chirag, 61, 301-303 (1990), English Abstract only, Reported in Biosis, 90, Abstract No. 432367 (1990).
Schwartz, R.S., et al., "Restenosis After Balloon Angioplasty--A Practical Proliferative Model in Porcine Coronary Arteries", Circulation, 82, 2190-2200 (Dec. 1990).
Schwartz, R.S., et al., "The Restenosis Paradigm Revisited: An Alternative Proposal for Cellular Mechanisms", JACC, 20, 1284-1293 (Nov. 1, 1992).
Sedlacek, S., "Estrogenic Properties of Tamoxifen on Serum Lipids in Postmenopausal Women with Breast Cancer (BCA)", Breast Cancer Research and Treatment, 14, p. 153, Abstract No. 82 (1989).
Shewmon, D.A., et al., "Tamoxifen Lowers Lp(a) in Males with Heart Disease", Cir., 86, Supplement I, p. I-388, Abstract No. 1345 (Oct. 1992).
Snow, A.D., et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells", Am. J. Path., 137, 313-330 (Aug. 1990).
Manasek, F.J., et al., "The Sensitivity of Developing Cardiac Myofibrils to Cytochalasin-B", PNAS (USA), 69, 308-312 (Feb. 1972).
Marzocchi, A., et al., Translation of "Restenosis after Coronary Angioplasty: Its Pathogenesis and Prevention", Cardiologia, 36, 309-
Grainger David J.
Metcalfe James C.
Weissberg Peter L.
Henley III Raymond
NeoRx Corporation
LandOfFree
Prevention and treatment of pathologies associated with abnormal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of pathologies associated with abnormal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of pathologies associated with abnormal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2426621